guadecitabine

Small moleculeexperimental

Chemistry & pharmacology

Loading structure…

SMILES

Nc1ncn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3O)[C@@H](CO)O2)c(=O)n1
Mol. weight
557.42 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • guadecitabine
  • guadecitabine
  • guadecitabine
  • guadecitabine
  • guadecitabine
  • sgi-110
  • sgi-110
  • sgi-110
  • sgi-110

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04340843Phase 2Apr 10, 2020National Cancer Institute (NCI), Yale University
NCT04250246Phase 2Mar 31, 2020Astex Pharmaceuticals, Inc., Bristol-Myers Squibb, Italian Network for Tumor Biotherapy, University of Siena
NCT03913455Phase 2May 31, 2019Astex Pharmaceuticals, Inc., Hoosier Cancer Research Network, Indiana University
NCT03576963Phase 1/Phase 2 (Phase 2)Oct 22, 2018Astex Pharmaceuticals, Inc., Bristol-Myers Squibb, National Cancer Institute (NCI), University of Southern California
NCT03454984Phase 2Sep 30, 2018Groupe Francophone des Myelodysplasies, Hôpital Saint Louis
NCT03603964Phase 2Jul 23, 2018Astex Pharmaceuticals, Inc.
NCT03257761Phase 1Feb 7, 2018National Cancer Institute (NCI), University of Southern California, Van Andel Research Institute
NCT03308396Phase 1/Phase 2 (Phase 2)Dec 19, 2017AstraZeneca, Big Ten Cancer Research Consortium, University of Michigan
NCT03206047Phase 1/Phase 2 (Phase 2)Sep 22, 2017National Cancer Institute (NCI), State University of New York, Buffalo
NCT03220477Phase 1Aug 4, 2017Astex Pharmaceuticals, Inc., Memorial Sloan-Kettering Cancer Center, Merck, Mirati Therapeutics Inc., Stand Up To Cancer, Van Andel Research Institute
NCT03179943Phase 2Aug 1, 2017Temple University
NCT03165721Phase 2Jul 4, 2017National Cancer Institute (NCI)
NCT03085849Phase 1Apr 1, 2017Columbia University
NCT02920008Phase 3Mar 16, 2017Astex Pharmaceuticals, Inc.
NCT02998567Phase 1Dec 1, 2016Astex Pharmaceuticals, Inc., Merck, Royal Marsden Hospital NHS Trust, University of London
NCT02901899Phase 2Nov 1, 2016Astex Pharmaceuticals, Inc., Merck, National Cancer Institute (NCI), Northwestern University
NCT02935361Phase 1/Phase 2 (Phase 2)Nov 1, 2016National Cancer Institute (NCI), University of Southern California
NCT02892318Phase 1Oct 31, 2016Roche
NCT02907359Phase 3Oct 1, 2016Astex Pharmaceuticals, Inc.
NCT02684162Phase 2Jun 1, 2016Astex Pharmaceuticals, Inc., University of Texas at Houston
Showing 20 of 33 trials
Page 1 / 2

Organizations

Research & Development (31)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Astex Pharmaceuticals, Inc.For profit18732010
National Cancer Institute (NCI)Government7322016
MerckFor profit3022016
University of Southern CaliforniaAcademic/Hospital3322016
University of Texas at HoustonAcademic/Hospital3312014
Bristol-Myers SquibbFor profit2012018
Groupe Francophone des MyelodysplasiesAcademic/Hospital2212014
Indiana UniversityAcademic/Hospital2122015
Italian Network for Tumor BiotherapyAcademic/Hospital2222015
Johns Hopkins UniversityAcademic/Hospital2222013
University of SienaAcademic/Hospital2022015
Van Andel Research InstituteAcademic/Hospital2012017
AstraZenecaFor profit1012017
Big Ten Cancer Research ConsortiumAcademic/Hospital1112017
Columbia UniversityAcademic/Hospital1112017
Cornell UniversityAcademic/Hospital1112016
Hoosier Cancer Research NetworkAcademic/Hospital1112019
Hôpital Saint LouisAcademic/Hospital1012018
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1112017
Mirati Therapeutics Inc.For profit1012017
31 organizations
Page 1 / 2